Exciva Secures €51 Million to Advance Alzheimer's Clinical Program

Andera Partners announced its participation in a €51 million Series B funding round for Exciva GmbH, a biopharmaceutical firm focused on neuropsychiatric treatments. The round, led by Gimv and EQT Life Sciences, aims to advance Exciva's lead program into a Phase 2 clinical study targeting agitation in Alzheimer's disease.

Deraphan, the company's lead compound, combines two CNS-active products, promising enhanced efficacy and a better risk/benefit profile compared to existing therapies. The clinical trial will take place in Europe, the UK, the US, and Canada. A completed Phase 1 trial demonstrated Deraphan's safety and tolerability.

Raphaël Wisniewski of Andera Partners expressed enthusiasm about the collaboration with European investors, noting the potential impact on Alzheimer’s treatment. The new board includes representatives from key investors and Exciva’s CEO, François Conquet.